ARA-290, also known as cibinetide, is a non-hematopoietic peptide derived from erythropoietin. It’s designed to activate the Innate Repair Receptor (IRR) and reduce inflammation by inhibiting the production of pro-inflammatory cytokines like TNFα. ARA-290 has shown promise in preclinical and clinical studies for treating conditions like type 2 diabetes, neuropathy, sarcoidosis, and age-related frailty.